CML Leukemic Stem Cell Response to Asciminib and TKIs

23.9 KB Excel file contains experimental data on the cytotoxic effects of asciminib, alone or combined with imatinib or nilotinib, on chronic myeloid leukemia cells. The dataset compares outcomes for leukemic stem cells and committed progenitors expressing high or low BCR::ABL1 transcript levels at diagnosis. It was authored by Michele Massimino and last updated in March 2026.

Use Cases

• Analyze the relationship between BCR::ABL1 transcript levels and the cytotoxic response of leukemic stem cells to asciminib.
• Compare the efficacy of asciminib monotherapy versus combinations with imatinib or nilotinib on Long-Term Culture-Initiating Cell (LTC-IC) frequency.
• Investigate the impact of asciminib and nilotinib combination on LTC-IC division rates and colony-forming unit (CFU) output.

Strengths

• Data is directly linked to a published research study on a novel therapeutic mechanism (STAMP compounds).
• Dataset is shared under a permissive CC BY 4.0 license for reuse.
• Focuses on a clinically relevant comparison of drug effects on two critical cell populations: leukemic stem cells and committed progenitors.

Limitations

• The dataset is very small at 23.9 KB, indicating limited scope and likely a summary table rather than raw experimental data.
• Specific data structure, column names, and row counts are not provided, complicating direct analytical use.
• Findings are specific to a particular experimental context and cell types, limiting generalizability.

Provenance

Source

Michele Massimino via figshare.

Collection Method

Experimental data from in vitro studies on patient-derived CML cells.

Freshness

Last updated March 2026.